���疫调节机制与信号 — Quick Reference

By Editorial Desk · published 2025-06-30 · last reviewed 2025-08-12 · Guide

prothymosin alpha raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-08-12 and is reviewed periodically as new material appears.

免疫调节机制与信号

胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。

在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。

临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。

Molecular Background and Identity

Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.

Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.

Thymosin-alpha-1 at a glance

Handling, Storage, and Analysis

Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.

Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.

Related pages on this site

• Lightweight workbook
• Gradual overview
• Focused primer
• Regional report
• Optimized guide
• Simple workbook
• Durable dataset
• Material analysis

Background and Mechanism of Action

Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.

Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.

Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.

Storage, Handling and Analytical Verification

Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.

Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.

Further detail

== Structural studies == As of late 2007, 7 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1AFS​, PDB: 1FJH​, PDB: 1FK8​, PDB: 1LWI​, PDB: 1RAL​, PDB: 2DKN​, and PDB: 2FVL​.

Fusion proteins or chimeric proteins (literally, made of parts from different sources) are proteins created through the joining of two or more genes that originally coded for separate proteins. Translation of this fusion gene results in a single or multiple polypeptides with functional properties derived from each of the original proteins. Recombinant fusion proteins are created artificially by recombinant DNA technology for use in biological research or therapeutics. Chimeric or chimera usually designate hybrid proteins made of polypeptides having different functions or physico-chemical patterns. Chimeric mutant proteins occur naturally when a complex mutation, such as a chromosomal translocation, tandem duplication, or retrotransposition creates a novel coding sequence containing parts of the coding sequences from two different genes. Naturally occurring fusion proteins are commonly found in cancer cells, where they may function as oncoproteins. The bcr-abl fusion protein is a well-known example of an oncogenic fusion protein, and is considered to be the primary oncogenic driver of chronic myelogenous leukemia. In the International nonproprietary name scheme, drugs based on fusion proteins are given the -fusp suffix.

At a temperature below the boiling point, any matter in liquid form will evaporate until reaching equilibrium with the reverse process of condensation of its vapor. At this point the vapor will condense at the same rate as the liquid evaporates. Thus, a liquid cannot exist permanently if the evaporated liquid is continually removed. A liquid at or above its boiling point will normally boil, though superheating can prevent this in certain circumstances. At a temperature below the freezing point, a liquid will tend to crystallize, changing to its solid form. Unlike the transition to gas, there is no equilibrium at this transition under constant pressure, so unless supercooling occurs, the liquid will eventually completely crystallize. However, this is only true under constant pressure, so that (for example) water and ice in a closed, strong container might reach an equilibrium where both phases coexist. For the opposite transition from solid to liquid, see melting. The phase diagram explains why liquids do not exist in space or any other vacuum. Since the pressure is essentially zero (except on surfaces or interiors of planets and moons) water and other liquids exposed to space will either immediately boil or freeze depending on the temperature. In regions of space near the Earth, water will freeze if the sun is not shining directly on it and vaporize (sublime) as soon as it is in sunlight. If water exists as ice on the Moon, it can only exist in shadowed holes where the sun never shines and where the surrounding rock does not heat it up too much.

Pseudouridine is an RNA modification that is introduced post-translationally, meaning after the RNA is transcribed. The proteins that facilitate this are called pseudouridine synthases (PUS) and are found in all kingdoms of life. Most research has been conducted on how PUS modify tRNA, so mechanisms involving snRNA and mRNA are not clearly defined. PUS can vary on RNA specificity, structure, and isomerization mechanisms. PUS enzymes are divided into five families which share an active sequence and important structural motifs.

Sources: en.wikipedia.org

Background from the literature

EMP is marketed in the United States, Canada, and Mexico under the brand name Emcyt, whereas the medication is marketed under the brand name Estracyt in the United Kingdom and elsewhere throughout Europe as well as in Argentina, Chile, and Hong Kong. It has been discontinued in a number of countries, including Australia, Brazil, Ireland, and Norway.

Cell death occurs when a cell ceases to carry out its functions, as a result of ageing, or types of cell injury (necrosis). Programmed cell death, including apoptosis, and autophagy is a natural process of replacing dead cells with new ones. A separate mode of cellular death is known as a mitotic catastrophe, which occurs during mitosis, following the improper progression of, or entrance to the cell cycle. This mechanism operates to prevent genomic instability. Other cell death pathways are described, and include anoikis, pyroptosis, mitoptosis, parthanatos, and necroptosis.

The company was losing money in the 1960s but remained under the control of the Salmon family, descended from a founding partner. Lyons began to close some of its London tea shops and hotels; in 1963 it also merged its LEO Computers business with English Electric's computer interests to form the jointly owned English Electric LEO. In 1964, Lyons sold their half-stake; and English Electric merged the company with Marconi's computer interests to form English Electric LEO Marconi Computers. A continuing problem in the British computer industry was both lack of investment capital and competition with the much larger U.S. computer companies, such as IBM. English Electric LEO Marconi Computers merged with other companies to form International Computers Limited (ICL) which was bought by Fujitsu in 1990. In 1978, Lyons was acquired by Allied Breweries and became part of the resulting Allied Lyons. It fell on hard economic times in the late 1980s; and was sold, eventually being broken up with its ice cream and ice lolly products, which were branded as Lyons Maid, being sold to Nestlé. Other parts that were sold off included Lyons Cakes (sold to RHM and ending up as part of their Manor Bakeries subsidiary which also makes Mr Kipling's Cakes) and Ready Brek cereal (ending up being owned by Weetabix Limited). At the end of 1994, Lyons sold Lyons Biscuits to Hillsdown Holdings, which later sold it to a U.S. investment firm which subsequently sold it to British biscuit manufacturer Burton's Foods. Lyons' cake products, such as Bakewell tart and Battenberg, are owned by Premier Foods.

Sources: en.wikipedia.org

Frequently asked questions